FDA AdComm Rejects Nuplazid This Time But Acadia’s Race Isn’t Run Yet
Summary: Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried and failed to expand its label...
Month: June 2022
Affimed: Preparing For Key Inflection Points
Summary: Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged...
Abercrombie & Fitch: Valuation Improving After The Drop
Summary: Abercrombie & Fitch released its Q1 results last month, managing to grow sales year-over-year despite difficult...
360 DigiTech: A Leader In An Oscillating Market
Summary: 360 DigiTech's core competencies of asset-light model and technology focus offer a bright future.In the first...
360 DigiTech: Undervalued Artificial Technology Stock With Certain Risks
Summary: 360 DigiTech, Inc. is a credit-tech platform that financial institutions use to provide better and targeted...
Ambarella Stock Forecast: Where Will It Be By 2025?
Summary: The higher valuation multiples for Ambarella relative to its peers are unjustified, taking into account its...
Mullen: Too Many Positive Catalysts Ahead
Summary: Mullen has a plethora of positive catalysts coming up in June. The official start date for the Fortune 500 company...
Even With Higher Rate And Inflation, Capital One Looks Good
Summary: Capital One saw a great year in 2021 due to the lowering of the allowance ratio, strong & healthy customers, and...
Is Ambarella A Buy After Earnings?
Summary: Ambarella operates in buzzword areas, but its growth has slowed.The company is generating losses and shows pro...
Ambarella: Not Ready To Roll, Just Yet
Summary: Ambarella cut guidance for current quarter revenues by a sizable amount due to supply chain issues.The chip...